prof. gisbert schneider, phd


Gisbert Schneider has been Full Professor of Computer-Assisted Drug Design at the Institute of Pharmaceutical Sciences in the Department of Chemistry and Applied Biosciences at ETH Zurich since 2010. His research is focussed on the development of methods for virtual screening, molecular de novo design and adaptive autonomous systems in drug research - Gisbert studied biochemistry, medicine and computer science at the Freie Universität Berlin, Germany, where he also earned his doctorate - his postdoc activity included work at the Benjamin Franklin University Clinic in Berlin, MIT, the University of Stockholm, and the Max-Planck-Institute of Biophysics in Frankfurt - Gisbert then spent five years working as a scientific specialist in industrial research at F. Hoffmann-La Roche - in 2000, he received the Venia Legendi for biochemistry and bioinformatics from the University of Freiburg, Germany- from 2002 to 2009, Gisbert worked as a full professor at the Goethe University in Frankfurt, Germany (Beilstein Endowed Chair for Chem- and Bioinformatics).

dan zabrowski, phd

development / regulatory

Dr. Zabrowski worked over 20 years for Roche in a number of key global leadership positions, including Global Head of Regulatory Affairs, Global Head of Development Operations, Global Head of Roche Pharma Partnering, President of Ventana Medical Systems and President of the Roche Sequencing Unit. During his tenure in Business Development and Diagnostics, Dr. Zabrowski and his teams delivered 300+ acquisition and partnership deals. In addition, he was Board member of Chugai Pharmaceuticals.
Prior to joining Roche, Dr. Zabrowski worked at Syntex, Fujisawa (now Astellas) and G.D. Searle in their pharmaceutical R&D organizations and served as Adjunct Assistant Professor at the School of Pharmacy, University of Illinois — Chicago. Dr. Zabrowski received his PhD in Organic Chemistry from Indiana University, Bloomington and his BA degree in Chemistry from Saint Louis University.

micha drukker, phd

stem cell biology

Dr. Micha Drukker is a principle investigator and the head of the human induced pluripotent stem cell core at the Helmholtz Institute in Munich. Micha is involved in basic and translational research in the stem cell field, and his achievements include the first analysis of the immunological properties of differentiated human embryonic stem (ES) cells, which has promoted the development of strategies to overcome the immunogenicity of human ES cells including by derivation of patient-matched pluripotent stem cells through therapeutic cloning and induction of pluripotency in somatic cells by reprogramming. More recently, Micha discovered cell surface markers enabling purification and monitoring of some of the earliest developmental progenitors from human ES cells mutually exclusively sorted from teratoma-initiating cells, and his most recent work focuses on the regulation of early pluripotent stem cell differentiation. Micha also leads projects aiming to produce and genetically engineer induced pluripotent stem cells for tissue restoration under clinical standards. Micha earned his BSc and PhD at the Hebrew University of Jerusalem, and did postdoctoral work at Stanford University.

brian ballios, md phd

clinical / translational

Dr. Brian Ballios is a Resident Physician and Senior Research Associate in the Department of Ophthalmology and Vision Sciences, University of Toronto. His team developed the first injectable biomaterial-based delivery system for stem cell transplantation in the retina. Brian also demonstrated a method to differentiate stem cell-derived photoreceptors with unprecedented efficiency to replace damaged photoreceptors in retinal degeneration, and has hence gained a deep understanding of retinal stem cells and their development.
His research is funded by the Foundation Fighting Blindness Canada, and Brian was the inaugural recipient of their Clinician-Scientist Emerging Leader Award. Dr. Ballios earned his MD and PhD degrees from the University of Toronto. Prior to this, he completed a degree in Engineering Chemistry from Queen’s University, with a focus on bioengineering and material science. His research interests lie at the intersection of stem cell biology, retinal development, and bioengineering.